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Originally identified as the enzymes responsible for catalysing the oxidation of specific, conserved proline residues within hypoxia-
inducible factor-1a (HIF-1a), the additional roles for the prolyl hydroxylase domain (PHD) proteins have remained elusive. Of the
four identified PHD enzymes, PHD2 is considered to be the key oxygen sensor, as knockdown of PHD2 results in elevated HIF
protein. Several recent studies have highlighted the importance of PHD2 in tumourigenesis. However, there is conflicting evidence as
to the exact role of PHD2 in tumour angiogenesis. The divergence seems to be because of the contribution of stromal-derived
PHD2, and in particular the involvement of endothelial cells, vs tumour-derived PHD2. This review summarises our current
understanding of PHD2 and tumour angiogenesis, focusing on the influences of PHD2 on vascular normalisation and
neovascularisation.
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The rapid growth of tumours results in their surpassing the
capacity of the established circulatory system to supply the
developing tumour with oxygen and nutrients as well as remove
waste products. For a tumour to expand, it must respond to these
assaults. Thus, a necessary step in the progression of any solid
tumour is adaptation to low oxygen or hypoxic conditions.
Tumour cells can respond to hypoxia by increasing oxygen
delivery or acclimating to decreased oxygen availability. The
hypoxia-inducible factor (HIF) family of transcription factors
mediates both the systemic and cellular response to hypoxia.
As master regulators of oxygen homeostasis, HIF-1 and HIF-2
must be tightly controlled to prevent the inappropriate expression
of hypoxia-induced genes. HIF-1 and HIF-2 are heterodimeric
transcription factors that are regulated at the post-translational
level. They are composed of a constitutive b-subunit (also known
as ARNT) and an oxygen-sensitive a-subunit. The a-subunit
is hydroxylated on two conserved proline residues by a family
of prolyl hydroxylases (Ivan et al, 2001; Jaakkola et al, 2001;
Yu et al, 2001). The hydroxylation of the a-subunits allows
the von Hippel-Lindau (VHL) E3 ubiquitin ligase to interact,
adding ubiquitin ladders and targeting the a-subunit to the
proteasome for degradation (Maxwell et al, 1999). HIF transactiva-
tion is also regulated by a third hydroxylation. This post-
translational modification of a conserved asparagine residue
(Asp 803 of HIF-1a and Asp 831 of HIF-2a) prevents the
interaction of HIF with p300, a transcriptional coactivator (Mahon
et al, 2001; Lando et al, 2002a,). Hydroxylation of the a-subunits
of HIF-1 and HIF-2 have critical roles in both the stability and
activity of HIF.
HYPOXIA-INDUCIBLE FACTORS AND CANCER
Under pathological conditions, strikingly in cancer, HIF becomes
deregulated and has a key role in the development of tumours.
Clinically, HIF is overexpressed in a variety of cancers, predicting
poorer prognosis (Zhong et al, 1999; Semenza, 2002). Experi-
mentally, HIF is required for the growth of solid tumours (Ryan
et al, 1998, 2000). Deletion of Hif-1a in teratoma tumour models
resulted in smaller tumours compared with teratomas containing
wild-type Hif-1a. Using transgenic mice, Hif-1a has been shown to
be an important factor in the development and metastatic spread
of a variety of cancers, including those of the breast and brain
(Tang et al, 2004; Liao et al, 2007; Du et al, 2008). Conversely, in
embryonic stem cells, deletion of Hif-1 reduced hypoxia-induced
apoptosis while increasing proliferation, resulting in larger
tumours (Carmeliet et al, 1998). The role of HIF in tumourigenesis
is further complicated by disparate findings for HIF-1 and HIF-2
(Acker et al, 2005; Gordan et al, 2008). However, tumour
promoting or activating mutations in the HIF sequence have not
been identified. A key upstream regulator of HIF is the VHL E3
ubiquitin ligase. VHL is a well-known tumour suppressor gene and
VHL disease is characterised by a distinct subset of highly vascular
tumours, notably renal carcinoma, angiomas, and hemangio-
blastomas (Kaelin, 2007). Mutation or silencing of VHL accounts
for 480% of all renal carcinomas, the most common form of
kidney cancer (Gnarra et al, 1993, 1994; Nickerson et al, 2008).
Nevertheless, inactivation of VHL by itself cannot explain the
broader variety of tumour types that have elevated HIF protein.
Another key regulator of HIF is the family of prolyl hydroxylases
(PHD1, PHD2, and PHD3) that modify HIF to be recognised by
VHL. The prolyl hydroxylases require oxygen and 2-oxyglutarate
as substrates and Fe(II) and ascorbate as cofactors, resulting in
oxidation of two highly conserved proline residues (Figure 1).
Recently, a paper by Ladroue et al (2008) identified a patient who
had a single amino acid substitution in the iron-binding pocket
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multiple paragangliomas. Furthermore, Kato et al (2006) reported
a high mutation rate of PHD2 in endometrial cancers. Mutations in
succinate dehydrogenase and fumarate hydratase, both compo-
nents of the citric acid cycle, have also been linked to tumour-
prone syndromes, resulting in part because of inhibition of the
PHDs (Isaacs et al, 2005; Ricketts et al, 2009). Overexpression of
PHD1 has been shown to inhibit tumour growth (Erez et al, 2003),
whereas PHD3 is downregulated in colorectal cancers (Xue et al,
2009). The complexity of interactions between HIFs and the PHDs
were highlighted by Henze et al (2010) who identified a negative
feedback loop in gliomas. Taken together, these findings suggest
that other negative regulators of HIF, such as the prolyl
hydroxylases, may contribute to tumourigenesis. However, the
role of PHDs in tumourigenesis is poorly defined.
THE ROLE OF PHD2 IN TUMOUR ANGIOGENESIS
Of the identified HIF prolyl hydroxylases, PHD2 is thought to be
the key oxygen sensor regulating HIF (Berra et al, 2003). Silencing
PHD2 through RNA interference increased HIF-1a levels under
normoxic conditions. This effect was not observed with either
PHD1 or PHD3. Furthermore, several groups independently
generated genetic knockout mice of the different Phds (Takeda
et al, 2006; Aragones et al, 2008; Minamishima et al, 2008). Phd1
and Phd3 homozygous knockout mice appeared phenotypically
normal with the expected Mendelian ratios (Takeda et al, 2006).
Meanwhile, homozygous knockout of Phd2 was embryonic lethal
between days 12.5 and 14.5, because of vascular defects of the
placenta and the heart. Moreover, conditional knockout of Phd2
increased vascular and capillary density, vessel branching, and
recruitment of vascular smooth muscle cells, whereas conditional
knockout of Phd1 and Phd3 did not have these vascular effects
(Takeda et al, 2007). Taken together, these data suggest that PHD2
may have an important role in regulating HIF and angiogenesis.
We recently identified PHD2 as a mediator of potent tumour
angiogenesis pathways (Chan et al, 2009) whereas Mazzone et al
(2009) reported a different function of PHD2 in vessel normal-
isation. We began our studies by analysing mRNA and protein
expression levels of PHD2 in human tumours. In colorectal
carcinomas, PHD2 levels of mRNA and protein were both
decreased in the tumour compared with non-involved, adjacent
normal colon tissue, suggesting that loss of PHD2 may influence
the tumour development. To further investigate, we used shRNA to
stably silence PHD2 in several different human cell lines, including
three colorectal cell lines and a pancreatic cell line. In each of these
lines, knocking down PHD2 levels did not affect in vitro cell
growth. It should be noted that we did not challenge these cells to
hypoxic stress or additional PHD inhibition. Henze et al (2010)
found that inhibiting PHD activity by hypoxia or DMOG reduced
glioma tumour cell survival in vitro. However, when we implanted
our cell lines as xenografts into the flanks of immunocompromised
mice, tumour growth was significantly and dramatically increased
compared with wild-type control cells. As the best-characterised
target of PHD2 is HIF, we then investigated whether the enhanced
tumour growth of PHD2 loss is dependent on HIF
Using HCT116 cells, a colon carcinoma, deleted for HIF-1a
(Dang et al, 2006), we then silenced PHD2 and implanted these
cells as tumours. Tumours that lacked HIF and PHD2 grew faster
than control tumours that only lacked HIF. This provocative
finding suggests that PHD2 has additional functions that are
independent of HIF.
To determine the mechanism of why tumours with PHD2 silenced
grew faster, we sectioned the tumours. TUNEL analysis showed no
difference between control and knockdown tumours, showing that
the wild-type tumours were not smaller because of an increase in
apoptosis. However, Ki67 expression, a marker of proliferation,
indicated that the PHD2-silenced tumours grew better than wild-
type tumours in vivo. These results suggested that PHD2 disruption
in tumour cells altered their interaction with the tumour
microenvironment, allowing for more efficient growth. We further
stained the tumour sections for CD31, a marker of blood vessels,
which showed a three- to four-fold increase in tumour blood vessels
in the tumours with PHD2 silenced. Similarly, several additional
groups have also found that PHD2 can influence tumour growth
through its effect on angiogenesis. Lee et al (2008) showed
that a reduction in PHD2 leads to enhanced tumour growth and
enhanced tumourigenesis. In reciprocal experiments, Matsumoto
et al (2006, 2009) found that 2-oxogluturate, a substrate of PHD2,
reduced both tumour growth and angiogenesis. Examining the effect
of Phd2 deletion on endothelial cells directly, Takeda and Fong
(2007) found that loss of Phd2 impaired proliferation. Thus, it
seemed likely that the enhanced tumour blood supply of the PHD2
knockdown tumour was providing the necessary components to
increase tumour growth.
We then investigated whether the PHD2 knockdown cells were
secreting factors capable of influencing angiogenesis. Using a
standard in vitro angiogenesis assay of endothelial cell tube
formation, conditioned media from PHD2 knockdown HCT116
cells were able to cause primary endothelial cells plating on
matrigel to aggregate, forming complex, tube-like structures.
Conditioned media from control HCT116 cells, which do not have
PHD2 knocked down, however, lacked the components to induce
the endothelial cells to branch. Subjecting the conditioned media
to an angiogenesis antibody array, we revealed that PHD2
consistently regulates angiogenin (ANG) and IL-8, two known
soluble pro-angiogenic factors. Conditioned media from HCT116
cells that had PHD2 knocked down had elevated protein levels
of ANG and IL-8. Notably, the levels of VEGF were unchanged
by PHD2 levels. Silencing either ANG or IL-8 impaired both angio-
genesis and tumourigenesis. These results suggested that PHD2
normally functions to inhibit angiogenesis and that silencing
PHD2 promotes angiogenesis.
2-oxoglutarate
O2
Succinate
CO2
PHD
P564 P402 P564(OH) P402(OH)
Ascorbate
Fe2+
HIF-1α HIF-1α
Ub
Ub Ub
Ub
VHL
Degradation Transactivation
(e.g. VEGF, Glut1, PAI-1,
MSH1, DEC1, Oct4, TERT,
MIF1, Twist, LOX, EGFR…)
HIF-1β
Figure 1 In the presence of oxygen, a family of prolyl hydroxylases
oxidises HIF-1a, leading to interaction with VHL and subsequent
degradation. Conversely, when the prolyl hydroxylases are not active,
HIF-1a is stabilised, interacts with HIF-1b, and is transcriptionally active.
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processes: angiogenesis, which is local sprouting, and vasculogenesis,
which is the de novo production of new blood vessels. Angiogenesis
is the formation of new blood vessels from pre-existing vessels. This
local angiogenesis can also send signals to the bone marrow, which
can in turn release precursor or progenitor cells to induce
neovascularisation. This process of blood vessel formation by
de novo production of endothelial cells, or vasculogenesis, requires
tumour cells to interact with stromal cells and circulating bone
marrow-derived cells (BMDCs). We then investigated whether PHD2
knockdown affected recruitment of BMDCs to the growing tumour
vasculature. To determine this we stained for two BMDC markers,
CD11b and CD45. CD11b is a marker of myeloid–monocytic
precursors, whereas CD45 is a myeloid marker. PHD2 silencing
increased mobilisation of BMDCs to the growing tumour, whereas
silencing of ANG and IL8 impaired this mobilisation. Thus, PHD2
functions to regulate both angiogenesis and vasculogenesis through
ANG and IL-8.
The PHD2 regulation of tumour vasculature through ANG and
IL-8 is independent of HIF. Cummins et al (2006) showed that
PHD1 could regulate IKKb, an inhibitor of NF-kB, which suggested
that PHD2 might also regulate NF-kB. In PHD2-silenced cells,
NF-kB activity was elevated and mutation of the NF-kB sites in the
promoters of ANG and IL-8 impaired NF-kB activation. Further-
more, IL-8 is a well-characterised NF-kB target and NF-kB bound
to the promoter of ANG, as determined by chromatin immuno-
precipitation, showing that the influence of PHD2 on the tumour
vasculature is mediated through NF-kB activity on ANG and IL-8,
two known pro-angiogenic factors. Transient silencing of p65,
an essential subunit of the NF-kB complex, impaired in vitro
angiogenesis. Using breast cancer data sets, there was a strong,
inverse correlation between PHD2 mRNA levels and NF-kB activity
profiles as well as negative relationship between PHD2 and CD31
mRNA levels, as determined by microarray analysis. Furthermore,
NF-kB activity profiles positively correlated with an increase in
CD31 mRNA. Taken together, these data illustrate that PHD2 can
regulate the tumour vasculature through an HIF-independent
mechanism but relies in part on inhibition of NF-kB and the
downstream targets of ANG and IL-8.
STROMAL PHD2 CONTRIBUTIONS TO METASTASIS
AND VESSEL NORMALISATION
In a parallel study, Mazzone et al (2009) investigated the stromal
role of PHD2 in the development of tumours. Interestingly, using
genetically modified mice that were heterozygous for Phd2,
they saw no difference in ectopic, primary tumour growth. In an
orthotopic, pancreatic model, tumours grown in wild-type
mice were more invasive and had more metastatic disease
compared with Phd2
þ/  mice. This phenotype was attributed to
higher intravasation of tumour cells into blood vessels of
wild-type vs Phd2 heterozygous animals. The Phd2 heterozygous
animals had higher expression of VE-cadherin and less hypoxia
based on pimonodozole staining, oxymetry, and HIF protein
levels. Tumours implanted into Phd2
þ/  mice also had less
necrosis and lower metabolic rates. The same researchers
showed that vessels of tumours implanted in heterozygous mice
were normalised compared with those of wild-type mice. The
vessel normalisation of tumours in Phd2 heterozygous mice
resulted in less intravasation of tumour cells and consequently
less metastasis.
In contrast to our findings, this group (Mazzone et al, 2009) saw
equivalent tumour vessel density between the heterozygous Phd2
and wild-type mice. However, despite equal numbers of tumour
vessels, the tumours of the Phd2
þ/  mice had smoother, more
regular, and more mature blood vessels that were not as
malformed or as leaky as tumours implanted in wild-type mice.
These researchers suggested that the tumour vessels formed in the
Phd2 heterozygous mice were ‘normalised,’ comparable to normal
blood vessels. Examining the angiogenic profile of Phd2 hetero-
zygous endothelial cells as well as tumour endothelial cells from
tumours implanted into Phd2
þ/  mice, they found higher soluble
Flt1 and VE-cadherin expression at the mRNA and protein levels,
respectively. Soluble Flt1 and VE-cadherin are two angiogenic
factors implicated in vessel normalisation and more specifically,
cell motility and cytoskeletal reorganisation. Interestingly,
in response to VEGF, endothelial cells heterozygous for Phd2
proliferated slower, had decreased motility, less lamellipodia
formation, and less apoptosis. The effects of sFlt1 and VE-cadherin
were dependent on HIF2 and not HIF1, as transient silencing of
only HIF2 decreased levels of both angiogenic factors. Taken
together, Mazzone et al (2009) found that stromal PHD2 functions
to regulate vessel normalisation, providing tighter junctions and
preventing metastatic spread.
CONCLUSIONS: VESSEL NORMALISATION
VS INCREASED VASCULATURE
The simplest explanation for these apparent discrepancies between
our study and that of Mazzone et al (2009) is differences in the
experimental models. We examined the influence of PHD2 loss on
tumour growth, whereas they examined the influence of the host
on tumour growth. We used shRNA to silence PHD2 in human cell
lines, which were then implanted as xenografts into immuno-
compromised mice. In comparison, Carmeliet et al (1998)
used syngeneic mouse cell lines inoculated into the flanks or
orthotopically implanted into immunocompetent but heterozygous
Phd2 mice. Our study examined the role of PHD2 in a tumour to
contribute to its growth through angiogenesis and recruitment of
bone marrow-derived cells (Figure 2A). The complimentary study
examined the function of stromal PHD2 in regulating tumour
metastasis (Figure 2B). Simultaneous investigations into the
NF-κB
ANG
Vasculogenesis Angiogenesis
Phd2+/+ Phd2+/–
PHD2
IL-8
Figure 2 (A) Loss of PHD2 in a tumour results in activation of NF-kB. In
turn, NF-kB upregulates ANG and IL-8 that promote both angiogenesis
and bone marrow-derived cell recruitment. These two complementary
pathways drive tumour growth. (B) Tumours implanted into Phd2
þ/þ
mice have irregular and leaky vessels, whereas those implanted into
Phd2
þ/  mice have ‘normalised’ vessels.
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delineate the responsibilities of PHD2. Furthermore, using
spontaneous tumour models as well as specific knockout in
various cell types may help elucidate HIF-dependent and HIF-
independent functions of PHD2.
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